Oncocept is an advanced genetic testing panel that analyzes a large number of genes associated with cancer. This test uses modern technologies such as NGS (Next Generation Sequencing) to identify mutations that may help with diagnosis, prognosis, and treatment selection.
These panels analyze circulating tumor DNA in the blood (ctDNA) and may provide molecular information without requiring material to be collected directly from the tumor, when clinically appropriate.
Molecular profiling may help the medical team with:
Test results are always interpreted in the context of the diagnosis, clinical history, histopathological findings, and the oncologist’s assessment.
Depending on the selected panel, OncoCEPT can analyze a wide range of genetic alterations, including:
The combination of DNA + RNA may provide a more comprehensive molecular profile of the tumor.
In most cases, tumor tissue is used, often an FFPE (Formalin-Fixed Paraffin-Embedded) block obtained from a biopsy or surgical procedure.
Some laboratories also specify the use of fresh tissue under appropriate transportation conditions.
A blood sample is used, from which circulating tumor DNA (ctDNA) is analyzed.
Depending on the panel and hematological condition, the sample may be peripheral blood. The type of sample is determined according to the requested panel and the recommendation of the laboratory or physician.
The Oncocept™ test is analyzed at Neuberg Diagnostics, a laboratory specializing in molecular diagnostics.
Test results are available within 40 business days.
Oncocept™ is an advanced genetic test that analyzes genetic alterations associated with tumors, providing molecular information that may help physicians assess and manage the disease.
The test analyzes a broad panel of genes to identify genetic alterations that may be relevant to the molecular characterization of the tumor and to guide further therapeutic decisions.
The test may be recommended for patients diagnosed with a tumor, particularly when molecular information may help determine further treatment options. The recommendation is made by the physician based on the individual clinical case.
Depending on the case and the available material, the analysis may be performed using tumor tissue obtained during diagnostic or surgical procedures. The physician or laboratory determines the appropriate material for analysis.
Samples for the Oncocept™ test are analyzed at Neuberg Diagnostics.
Oncocept™ does not replace histopathological examination and clinical assessment. It provides molecular/genetic information that is interpreted together with the patient’s other clinical data.
The result may provide important information for the physician when assessing the molecular characteristics of the tumor and considering therapeutic options. Treatment decisions are made by the specialist physician.
Yes. It is recommended that the test be performed after an assessment by a specialist physician, who determines whether the analysis is appropriate for the clinical situation.
For information about the procedure, required material, and sample submission, please contact Pentagene Genetics before having the test performed.
